---
title: "Kelun-Biotech Wins NMPA IND Nod for ITGB6-Targeted ADC SKB105 and Advances Oncology Collaboration With Crescent"
type: "News"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/271423563.md"
description: "Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. has received Investigational New Drug approval from China's NMPA for SKB105, an integrin beta-6-targeted antibody-drug conjugate for advanced solid tumors. The company is advancing its oncology collaboration with Crescent Biopharma, which holds ex-China rights to SKB105 while Kelun retains Greater China rights. The latest analyst rating for Kelun's stock (HK:6990) is a Buy with a price target of HK$545.00, reflecting positive market sentiment towards the company's oncology portfolio and growth strategy."
datetime: "2026-01-04T12:07:13.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/271423563.md)
  - [en](https://longbridge.com/en/news/271423563.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/271423563.md)
---

> 支持的语言: [English](https://longbridge.com/en/news/271423563.md) | [繁體中文](https://longbridge.com/zh-HK/news/271423563.md)


# Kelun-Biotech Wins NMPA IND Nod for ITGB6-Targeted ADC SKB105 and Advances Oncology Collaboration With Crescent

### Claim 70% Off TipRanks This Holiday Season

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

The latest update is out from Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H ( (HK:6990) ).

Sichuan Kelun-Biotech has received Investigational New Drug approval from China’s National Medical Products Administration for SKB105 (CR-003), an internally developed integrin beta-6–targeted antibody-drug conjugate for the treatment of advanced solid tumors, enabling the company to advance this differentiated oncology asset into clinical development. The company also highlighted its strategic collaboration with Crescent Biopharma, under which Crescent holds ex-China rights to SKB105/CR-003 and Kelun-Biotech retains Greater China rights while gaining Greater China rights to SKB118/CR-001, a PD-1 x VEGF bispecific antibody for solid tumors, positioning the company to build a complementary oncology portfolio and expand its presence in both domestic and global cancer therapeutics markets.

The most recent analyst rating on (HK:6990) stock is a Buy with a HK$545.00 price target. To see the full list of analyst forecasts on Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H stock, see the HK:6990 Stock Forecast page.

**More about Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H**

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. is a China-based biopharmaceutical company focused on developing innovative oncology therapies, including antibody-drug conjugates (ADCs) and bispecific antibodies. Its pipeline targets advanced solid tumors, with a geographic strategy that leverages partnerships to access markets outside Greater China while retaining commercialization rights domestically.

**Average Trading Volume:** 615,330

**Technical Sentiment Signal:** Buy

**Current Market Cap:** HK$93.41B

### 相关股票

- [Crescent Biopharma (CBIO.US)](https://longbridge.com/zh-CN/quote/CBIO.US.md)

## 相关资讯与研究

- [Is It Time To Reconsider Agree Realty (ADC) After Recent Share Price Strength?](https://longbridge.com/zh-CN/news/278334866.md)
- [FDA Clears IND for Crescent Biopharma's CR-001 Targeting Solid Tumors](https://longbridge.com/zh-CN/news/271508765.md)
- [1 Under‑the‑Radar Biotech to Buy for Potential 10X Growth in the Next Decade](https://longbridge.com/zh-CN/news/278573307.md)
- [Kainova reports positive top line results from Phase I EPRAD trial](https://longbridge.com/zh-CN/news/278702903.md)
- [Forget AI Stocks: This Potentially Disruptive Biotech Could Soar By 181%, According to Wall Street](https://longbridge.com/zh-CN/news/278409062.md)